Applicants are encouraged to review the new 2022 SBIR and STTR Omnibus Funding Opportunities (FOAs). These FOAs encourage small businesses to submit grant applications to NIH, CDC, and FDA for innovative ideas across the HHS mission space. The new FOAs are listed below:

PA-22-176: PHS 2022-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)

PA-22-177: PHS 2022-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required)

PA-22-178: PHS 2022-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)

PA-22-179: PHS 2022-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent STTR [R41/R42] Clinical Trial Required)

2022 SBIR/STTR Program Descriptions and Research Topics Document  

2022 SBA-Approved Waiver Topics 

SF424 SBIR/STTR Application Manual (Forms-G) (Due Dates before January 25^th, 2023)

SF424 SBIR/STTR Application Manual (Forms-H) (Due Dates after January 25^th, 2023)